Navigation Links
Surefire Medical's Anti-Reflux Infusion System May Eliminate Coiling, Lower Cost Of Embolization Procedures
Date:9/16/2013

WESTMINSTER, Colo., Sept. 16, 2013 /PRNewswire/ -- Surefire Medical, Inc., the developer of a brand new class of infusion systems designed to maximize direct-to-tumor drug delivery without reflux, today announced that presentations at the Cardiovascular and Interventional Radiological Society (CIRSE) meeting make the economic case for use of the new Surefire Infusion System (SIS).   Research presented today in Barcelona found that:

  • The SIS catheter group had a significant reduction in procedure time, fluoroscopy time, and contrast dose in pre-treatment angiograms
  • Without use of coils, no non-target embolization occurred in the SIS group during treatment
  • Using the SIS catheter to protect non-target organs costs significantly less than coil embolization in direct-to-tumor cancer treatment

"The Surefire Infusion System is a viable first-line alternative to traditional retrievable coil embolization for protecting non-target organs and may lead to decreased overall costs, procedure time, fluoroscopy time, and contrast exposure when treating cancer patients with radioembolization," said principal investigator Steven Kikolski, MD of the University of California San Diego (UCSD).

Additional SIS-focused presentations at CIRSE

Five additional presentations and posters at CIRSE focusing on the Surefire Infusion System

  • Confirm the safety of performing chemoembolization and radioembolization procedures without coiling
  • Present a pilot study of a single procedure for mapping and radioembolization
  • Detail the new ability to measure blood pressure changes that can signal the endpoint of embolization
  • Discuss the feasibility of bariatric embolization to reduce obesity

"We are extremely gratified by the rapidly growing body of clinical evidence showing that both patients and medical institutions benefit by the use of the Surefire Infusion System for cancer treatment," said Surefire President and CEO Jim Chomas.  "The new technology advances the better tolerated, minimally-invasive embolization techniques.  It reduces procedure time and cost, and makes treatment feasible for patients previously thought untreatable."

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets.  Surefire's infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue.  The Surefire Infusion System-ST, LT and specialty catheters have received regulatory approval in the U.S., Europe, and New Zealand.  For more information, please visit www.surefiremedical.com.

CIRSE BOOTH #1


'/>"/>
SOURCE Surefire Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Surefire Medical Launches Next Generation Infusion System ST-LT and Specialty Catheters at SIR - Maximizing Targeted Delivery of Embolics Without Reflux
2. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
3. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
4. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
5. Dicom Systems and USARAD.com Announce Partnership and Introduce Beta Version of XMRI.com, New System by USARAD.com
6. Ellmans Pelleve™ Wrinkle Reduction System featured in "Sexy Eyes" segment on The Doctors
7. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
8. BioPower Systems Awarded $5 Million from Victorian Government
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
11. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... Baltimore, MD (PRWEB) , ... May 20, 2016 , ... ... contaminated with Listeria, as reported by Food Safety News on May 12, 2016(1), demonstrates ... according to Ted Olsen, CEO of Baltimore-based biotech firm, PathSensors, Inc. ...
(Date:5/19/2016)... SAN DIEGO , May 19, 2016 /PRNewswire/ ... (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced ... at creating the first cord blood based cancer ... a provisional patent application, Regen described a generation ... activity was potentiated by gene silencing.  The product ...
(Date:5/18/2016)... ... May 18, 2016 , ... STACS DNA Inc., the sample tracking software ... report sexual assault kit processing to help them save time and reduce errors. , ... kits to be processed and victims informed of results. Due to a previous lack ...
(Date:5/17/2016)... McKinney, Texas (PRWEB) , ... May 17, 2016 ... ... product for use in animal waste reduction applications, announced today it will be ... Des Moines, Iowa. , ManureMagic™ was featured in the Wall Street Journal last ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):